ArticleCell communication and signaling : CCS2025
C3G deregulation uncovers a dual role in B-cell lymphoma: tumor suppression and enhanced metastasis via Rap1 and Rac2 signaling.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundC3G (RapGEF1) is a guanine nucleotide exchange factor that activates Rap1, a small GTPase implicated in hematologic malignancies. We previously showed that C3G GEF activity is self-repressed via its AIR (autoinhibitory region). A lymphoma-associated missense mutation (Y554H) disrupts this inhibition, resulting in constitutive activation. This study aims to investigate the consequences of C3G dysregulation in B-cell lymphoma.
methodsMurine C3G mutation Y564H (equivalent to human Y554H) was introduced into the A20 B-cell lymphoma line using CRISPR/Cas9. Rap1 activation, proliferation, apoptosis, ERK1/2 phosphorylation, Rac2 activity, adhesion, migration, invasion, tumorigenicity, and transcriptomic changes were assessed through biochemical assays, in vitro functional studies, in vivo mouse models, and RNA-seq analysis.
resultsA20-C3G-Y564H cells exhibited increased Rap1 activation under both basal and stimulated conditions. Hyperactivation of the C3G-Rap1 pathway impaired proliferation, promoted apoptosis, and was associated with reduced ERK1/2 phosphorylation. Furthermore, Rac2 activity was diminished, correlating with altered adhesion properties. Consistently, cell migration and invasion were enhanced, in correspondence with an increased number of metastatic foci in the liver following tail vein injection into syngeneic BALB/c mice. Notably, reduced C3G expression further augmented the metastatic potential of A20 cells. RNA-seq analysis revealed widespread transcriptional changes involving Rac2 signaling, adhesion, and metastatic pathways.
conclusionsC3G plays a dual role in B-cell lymphoma: it acts as a tumor suppressor by inhibiting growth and promoting apoptosis, but may also facilitate metastasis via enhanced motility. This dual effect likely reflects a functional balance between Rap1 and Rac2 signaling. These findings underscore the complexity of C3G-regulated pathways in B cells and suggest that C3G may serve as a potential novel marker in hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.